References
1. Iglesias P, Diez JJ. Management of endocrine disease: a clinical
update on tumor-induced hypoglycemia. Eur J Endocrinol. 2014
Apr;170(4):R147-57.
2. Dynkevich Y, Rother KI, Whitford I, Qureshi S, Galiveeti S, Szulc AL,
et al. Tumors, IGF-2, and hypoglycemia: insights from the clinic, the
laboratory, and the historical archive. Endocr Rev. 2013
Dec;34(6):798-826.
3. Sharma M, Reddy DN, Kiat TC. Refractory Hypoglycemia Presenting as
First Manifestation of Advanced Hepatocellular Carcinoma. ACG Case Rep
J. 2014 Oct;2(1):50-2.
4. Bodnar TW, Acevedo MJ, Pietropaolo M. Management of non-islet-cell
tumor hypoglycemia: a clinical review. J Clin Endocrinol Metab. 2014
Mar;99(3):713-22.
5. Dutta P, Aggarwal A, Gogate Y, Nahar U, Shah VN, Singla M, et al.
Non-islet cell tumor-induced hypoglycemia: a report of five cases and
brief review of the literature. Endocrinol Diabetes Metab Case Rep.
2013;2013:130046.
6. Livingstone C. IGF2 and cancer. Endocr Relat Cancer. 2013
Dec;20(6):R321-39.
7. Teale JD, Marks V. Inappropriately elevated plasma insulin-like
growth factor II in relation to suppressed insulin-like growth factor I
in the diagnosis of non-islet cell tumour hypoglycaemia. Clin Endocrinol
(Oxf). 1990 Jul;33(1):87-98.
8. Teale JD, Wark G. The effectiveness of different treatment options
for non-islet cell tumour hypoglycaemia. Clin Endocrinol (Oxf). 2004
Apr;60(4):457-60.
9. Huang JS, Chang PH. Refractory hypoglycemia controlled by systemic
chemotherapy with advanced hepatocellular carcinoma: A case report.
Oncol Lett. 2016 Jan;11(1):898-900.
10. Teale JD, Marks V. Glucocorticoid therapy suppresses abnormal
secretion of big IGF-II by non-islet cell tumours inducing hypoglycaemia
(NICTH). Clin Endocrinol (Oxf). 1998 Oct;49(4):491-8.